4D Molecular Therapeutics FDMT Earnings yield
Earnings yield at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: 4D Molecular Therapeutics’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's earnings yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's earnings yield?
- 4D Molecular Therapeutics (FDMT) reported earnings yield of -51.5% in Q3 2025.
- How has 4D Molecular Therapeutics's earnings yield changed year-over-year?
- 4D Molecular Therapeutics's earnings yield decreased by 114.7% year-over-year, from -24% to -51.5%.
- What is the long-term trend for 4D Molecular Therapeutics's earnings yield?
- Over 4 years (2020 to 2024), 4D Molecular Therapeutics's earnings yield has grown at a 86.9% compound annual growth rate (CAGR), from -5.1% to -62.5%.
- What does earnings yield mean?
- Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.